jay gw
26th October 2006, 06:33 PM
Scientists helping to develop the next generation of cancer-beating drugs say they have had a major breakthrough with their latest results.
A new class of drugs – being developed by a major pharmaceutical company – targets an enzyme that helps cells divide; in cancer, this enzyme, called Aurora B, goes into overdrive, possibly leading to uncontrolled and abnormal cell divisions.
The University of Manchester team has been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and has proven very effective at killing cancer cells in cultures grown in the laboratory. "The first compounds were designed to inhibit a related enzyme called Aurora A," said Dr Stephen Taylor, who is leading the research in Manchester's Faculty of Life Sciences.
"But our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells and we have been strongly encouraged by these latest results."
The research – published in the Journal of Cell Science – will be of interest to scientists around the world looking at Aurora inhibitors; there are currently more than 10 companies pursuing Aurora cancer programmes. "Auroras have attracted worldwide attention but no one has been entirely sure which strategy to follow," said Dr Taylor.
http://www.eurekalert.org/pub_releases/2006-10/uom-ncd102606.php
A new class of drugs – being developed by a major pharmaceutical company – targets an enzyme that helps cells divide; in cancer, this enzyme, called Aurora B, goes into overdrive, possibly leading to uncontrolled and abnormal cell divisions.
The University of Manchester team has been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and has proven very effective at killing cancer cells in cultures grown in the laboratory. "The first compounds were designed to inhibit a related enzyme called Aurora A," said Dr Stephen Taylor, who is leading the research in Manchester's Faculty of Life Sciences.
"But our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells and we have been strongly encouraged by these latest results."
The research – published in the Journal of Cell Science – will be of interest to scientists around the world looking at Aurora inhibitors; there are currently more than 10 companies pursuing Aurora cancer programmes. "Auroras have attracted worldwide attention but no one has been entirely sure which strategy to follow," said Dr Taylor.
http://www.eurekalert.org/pub_releases/2006-10/uom-ncd102606.php